KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Deferred Revenue: 2020

Historic Current Deferred Revenue for Castle Biosciences (CSTL) over the last 1 years, with Dec 2020 value amounting to $6.6 million.

  • Castle Biosciences' Current Deferred Revenue fell 64.08% to $3.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.0 million, marking a year-over-year decrease of 64.08%. This contributed to the annual value of $6.6 million for FY2020, which is N/A change from last year.
  • According to the latest figures from FY2020, Castle Biosciences' Current Deferred Revenue is $6.6 million.
  • Over the past 5 years, Castle Biosciences' Current Deferred Revenue peaked at $6.6 million during FY2020, and registered a low of $6.6 million during FY2020.
  • Moreover, its 1-year median value for Current Deferred Revenue was $6.6 million (2020), whereas its average is $6.6 million.